Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 Chemoprotection in Breast Cancer
NCT05622058Phase 1Terminated
- Sponsor
- Rein Therapeutics
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of sulanemadlin in myelosuppression and Chemotherapy-induced alopecia (CIA), sponsored by Rein Therapeutics. Primary endpoints: Safety and tolerability of ALRN-6924 in combination with TAC chemotherapy at 24 weeks and Chemoprotective effects of ALRN-6924 on bone marrow toxicities at 3 weeks. Started Jan 2023; status: terminated.
02
Drugs
sulanemadlin
03
Conditions
myelosuppressionChemotherapy-induced alopecia (CIA)
Beyond the preview
Go deeper on NCT05622058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622058.